Marathon Asset Management exited 300,000 shares of Cinemark Holdings in the fourth quarter.
The quarter-end position value decreased by $8.41 million, reflecting the share sale.
The position was previously 11.2% of the fund's AUM as of the prior quarter.
On February 17, 2026, Marathon Asset Management disclosed in an SEC filing that it sold out its entire Cinemark Holdings (NYSE:CNK) position, an estimated $8.41 million trade based on last-disclosed position values.
Marathon Asset Management reported in a recent SEC filing dated February 17, 2026, that it fully liquidated its Cinemark Holdings stake during the fourth quarter of 2025. The quarter-end value of the Cinemark position decreased by $8.41 million, reflecting the share sale.
| Metric | Value |
|---|---|
| Revenue (TTM) | $3.1 billion |
| Net Income (TTM) | $136.6 million |
| Dividend Yield | 1.30% |
| Price (as of market close 2/17/26) | $25.36 |
Cinemark Holdings together with its subsidiaries, engages in the motion picture exhibition business. The company was founded in 1984 and is headquartered in Plano, Texas. Cinemark leverages its extensive theatre network and premium offerings to drive attendance and capture a broad customer base. Strategic focus on operational efficiency and diversified revenue streams supports its competitive positioning within the global entertainment industry.
This move highlights the challenge of investing in businesses that depend heavily on consumer behavior and unpredictable content cycles. Movie theater operators like Cinemark can deliver strong cash flow when the film slate hits, but the ride for shareholders is rarely smooth.
Cinemark’s latest results showed a business that is stabilizing after the pandemic era, even if earnings remain uneven from quarter to quarter. The company generated more than $3.1 billion in revenue during 2025, its highest annual total since theaters reopened, while producing about $578 million in adjusted EBITDA and $141 million in net income.
Those numbers demonstrate that theatrical exhibition is still a viable business, supported by blockbuster releases, premium viewing formats, and high-margin concession sales. Cinemark served roughly 193 million moviegoers in 2025 and generated a record $1.2 billion in concession revenue.
Still, the stock tells a different story. Shares plunged nearly 20% during the fourth quarter before rebounding sharply this year, underscoring how sentiment around theatrical releases and streaming competition can swing quickly. Within a portfolio largely centered on broad market exposure and industrial companies, a highly cyclical theater operator seemed like an outlier, and during tough times for the stock, conviction might be better focused elsewhere.
Before you buy stock in Cinemark, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Cinemark wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $532,066!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,122,072!*
Now, it’s worth noting Stock Advisor’s total average return is 960% — a market-crushing outperformance compared to 193% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of March 5, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends PayPal. The Motley Fool recommends UnitedHealth Group and recommends the following options: long January 2027 $42.50 calls on PayPal and short March 2026 $65 calls on PayPal. The Motley Fool has a disclosure policy.